Cited by 251Monoclonal and Polyclonal Antibodies ResearchHistorical Medical Research and TreatmentsBacterial Infections and Vaccines

The DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index.

Serum therapy revisited: animal models of infection and development of passive antibody therapy

Open access

Casadevall, A, Scharff, M D·1994·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.38.8.1695PMC PMC284624

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1128/aac.38.8.1695

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Continuous cultures of fused cells secreting antibody of predefined specificity
Köhler, G., & Milstein, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,200
The principles and practice of medicine
(1938) · The American Journal of Surgery · doi:10.1016/s0002-9610(38)91188-2 · Cited by 1,657
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
LoBuglio, A. F., Wheeler, R. H., Trang, J. M., Haynes, A., Rogers, K., Harvey, E. B., Sun, L., Ghrayeb, J., & Khazaeli, M. B. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.11.4220 · Cited by 524
Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy.
Schroff, R. W., Foon, K. A., Beatty, S. M., Oldham, R. K., & Morgan, A. C. (1985) · PubMed · Cited by 488
THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS
Flexner, S. (1913) · The Journal of Experimental Medicine · doi:10.1084/jem.17.5.553 · Cited by 175
THE FURTHER SEPARATION OF TYPES AMONG THE PNEUMOCOCCI HITHERTO INCLUDED IN GROUP IV AND THE DEVELOPMENT OF THERAPEUTIC ANTISERA FOR THESE TYPES
Cooper, G. M., Rosenstein, C., Walter, A. W., & Peizer, L. R. (1932) · The Journal of Experimental Medicine · doi:10.1084/jem.55.4.531 · Cited by 96
SEROLOGICAL RELATIONSHIPS AMONG MENINGOCOCCI
Branham, S. E. (1953) · Bacteriological Reviews · doi:10.1128/br.17.3.175-188.1953 · Cited by 84
In Vitro Antibodies: Strategies for Production and Application
Morrison, S. L. (1992) · Annual Review of Immunology · doi:10.1146/annurev.iy.10.040192.001323 · Cited by 83
Experimental Meningococcal Infection in Mice
Miller, C. P. (1933) · Science · doi:10.1126/science.78.2024.340 · Cited by 77
A BIOLOGIC CLASSIFICATION OF PNEUMOCOCCI BY MEANS OF IMMUNITY REACTIONS
Dochez, A. R. (1913) · JAMA · doi:10.1001/jama.1913.04350100005003 · Cited by 74

Flagged first, then by citations

Show all 84 references

1 of the 84 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 251

Naïve Human Antibody Libraries for Infectious Diseases
Chan, S. K., Rahumatullah, A., Lai, J. Y., & Lim, T. S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-72077-7_3 · Cited by 33
Convalescent serum therapy for COVID-19: A 19th century remedy for a 21st century disease
Montelongo‐Jauregui, D., Vila, T. V. M., Sultan, A. S., & Jabra‐Rizk, M. A. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008735 · Cited by 33
Characterization of Anticapsular Monoclonal Antibodies That Regulate Activation of the Complement System by theCryptococcus neoformansCapsule
Kozel, T. R., de Jong, B. C., Grinsell, M. M., MacGill, R. S., & Wall, K. K. (1998) · Infection and Immunity · doi:10.1128/iai.66.4.1538-1546.1998 · Cited by 33
Prospects for Development of a Vaccine to Prevent and Control Vaginal Candidiasis
Fidel, P. L., & Cutler, J. E. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0143-y · Cited by 32
Expanding the Reach of Monoclonal Antibodies: A Review of Synthetic Nucleic Acid Delivery in Immunotherapy
Chung, C. W., Kudchodkar, S. B., Chung, C. N., Park, Y. K., Xu, Z., Pardi, N., Abdel‐Mohsen, M., & Muthumani, K. (2023) · Antibodies · doi:10.3390/antib12030046 · Cited by 36
Application of egg yolk antibodies as replacement for antibiotics in poultry
Yegani, M., & Korver, D. R. (2010) · World s Poultry Science Journal · doi:10.1017/s0043933910000048 · Cited by 32
Severe COVID-19: Immunosuppression or Hyperinflammation?
Liu, Y., Li, Y., Xu, D., Zhang, J., & Peng, Z. (2021) · Shock · doi:10.1097/shk.0000000000001724 · Cited by 33
Modulation of the Lung Inflammatory Response to Serotype 8 Pneumococcal Infection by a Human Immunoglobulin M Monoclonal Antibody to Serotype 8 Capsular Polysaccharide
Burns, T., Abadi, M. A., & Pirofski, L. (2005) · Infection and Immunity · doi:10.1128/iai.73.8.4530-4538.2005 · Cited by 30
Crisis in Infectious Diseases: 2 Decades Later
Casadevall, A. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix067 · Cited by 32
Self-citation
Development of human monoclonal antibodies against diseases caused by emerging and biodefense-related viruses
Zhu, Z., Dimitrov, A. S., Chakraborti, S., Dimitrova, D., Xiao, X., Broder, C. C., & Dimitrov, D. S. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.1.57 · Cited by 30
The case for pathogen-specific therapy
Casadevall, A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903066837 · Cited by 28
Self-citation
Growth inhibition of Staphylococcus aureus by chicken egg yolk antibodies
Guimarães, M. C. C., Amaral, L. G., Rangel, L. B. A., Silva, I. V., Matta, C. G. F., & Matta, M. F. D. R. (2009) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-009-0041-x · Cited by 27
Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape
Hossain, M. S., Hami, I., Sawrav, M. S. S., Rabbi, M. F., Saha, O., Bahadur, N. M., & Rahaman, M. M. (2020) · Discoveries · doi:10.15190/d.2020.18 · Cited by 27
The methodology for determining the efficacy of antibody-mediated immunity
Casadevall, A. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.04.027 · Cited by 26
Self-citation
Monoclonal Antibody–Mediated Toxicity in Cryptococcus neoformans Infection: Mechanism and Relationship to Antibody Isotype
Lendvai, N. K., & Casadevall, A. (1999) · The Journal of Infectious Diseases · doi:10.1086/314946 · Cited by 25
Self-citation
Potential strategies for combating COVID-19
Shamim, S., Khan, M., Kharaba, Z. J., Ijaz, M., & Murtaza, G. (2020) · Archives of Virology · doi:10.1007/s00705-020-04768-3 · Cited by 24
Pneumococcal Capsular Polysaccharide Vaccine-Mediated Protection against Serotype 3Streptococcus pneumoniaein Immunodeficient Mice
Tian, H., Groner, A., Boes, M. L., & Pirofski, L. (2007) · Infection and Immunity · doi:10.1128/iai.01371-06 · Cited by 23
Potential Therapeutic Effects of Egg Yolk Antibody (IgY) in Helicobacter pylori Infections─A Review
Zhang, L., Xiao, Y., Ji, L., Lin, M., Zou, Y., Zhao, J., & Zhao, S. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c05398 · Cited by 22
The Assessment of Convalescent Plasma Efficacy against COVID-19
Casadevall, A., Grossman, B. J., Henderson, J. P., Joyner, M. J., Shoham, S., Pirofski, L., & Paneth, N. (2020) · Med · doi:10.1016/j.medj.2020.11.002 · Cited by 21
Self-citation
COVID-19: Diagnostics, Therapeutic Advances, and Vaccine Development
Majid, S., Khan, M. S., Rashid, S., Niyaz, A., Farooq, R., Bhat, S. A., Wani, H. A., & Qureshi, W. (2021) · Current Clinical Microbiology Reports · doi:10.1007/s40588-021-00157-9 · Cited by 21
Development of an anti-Pseudomonas aeruginosa therapeutic monoclonal antibody WVDC-5244
Horspool, A. M., Sen-Kilic, E., Malkowski, A. C., Breslow, S. L., Mateu-Borrás, M., Hudson, M. S., Nunley, M. A., Elliott, S., Ray, K., Snyder, G. A., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1117844 · Cited by 20
Practical Considerations for the Pharmacokinetic and Immunogenic Assessment of Antibody–Drug Conjugates
Sauerborn, M., & van Dongen, W. D. (2014) · BioDrugs · doi:10.1007/s40259-014-0096-z · Cited by 20
Back to the future: Antibody-based strategies for the treatment of infectious diseases
Oral, H. B., Özakın, C., & Akdiş, C. A. (2002) · Molecular Biotechnology · doi:10.1385/mb:21:3:225 · Cited by 19
Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarray
de Assis, R., Jain, A., Nakajima, R., Jasinskas, A., Khan, S., Davies, H., Corash, L., Dumont, L. J., Kelly, K. K., Simmons, G., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-87137-7 · Cited by 18
Respiratory tract microbiome and pneumonia
Narendrakumar, L., & Ray, A. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.07.002 · Cited by 17
Immunotherapy in Clinical Medicine: Historical Perspective and Current Status
Shahani, L., Singh, S., & Khardori, N. M. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.04.001 · Cited by 18
Emerging Therapeutic Strategies to Combat Antimicrobial Resistance in the Post‐Antibiotic Era
Mohammadzadeh, R., Shahbazi, S., Khodaei, N., & Sabzi, S. (2025) · Journal of Basic Microbiology · doi:10.1002/jobm.70070 · Cited by 20
Detection, prevention and treatment of COVID‐19 and opportunities for nanobiotechnology
Bao, Q., Yang, T., Yang, M., & Mao, C. (2022) · Open Research (University of Surrey) · doi:10.1002/viw.20200181 · Cited by 16
Human Polyclonal Antibodies Prevent Lethal Zika Virus Infection in Mice
Branche, E., Simon, A. Y., Sheets, N., Kim, K., Barker, D., Nguyen, A.-V. T., Sahota, H., Young, M. P., Salgado, R., Mamidi, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46291-9 · Cited by 16
Surgical Irrigation with Pooled Human Immunoglobulin G to Reduce Post-Operative Spinal Implant Infection
Poelstra, K. A., Barekzi, N. A., Slunt, J. B., Schuler, T. C., & Grainger, D. W. (2000) · Tissue Engineering · doi:10.1089/107632700418100 · Cited by 17
Role of Immunoglobulin Therapy to Prevent and Treat Infections
Katragkou, A., Roilides, E., & Walsh, T. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-77674-3_17 · Cited by 16
Gender differences in treatment of Coronavirus Disease-2019
Ambrosino, I., Barbagelata, E., Corbi, G., Ciarambino, T., Politi, C., & Moretti, A. M. (2020) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2020.1508 · Cited by 17
Measuring the quality of clinical veterinary services for Cattle: an application of a role play experiment in rural Uganda
Ilukor, J., & Regina Birner, B. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-894 · Cited by 16
Overview of antibody‐mediated immunity to S. pneumoniae: pneumococcal infections, pneumococcal immunity assessment, and recommendations for IG product evaluation
Sorensen, R. U., & Edgar, D. (2018) · Transfusion · doi:10.1111/trf.15044 · Cited by 16
Evaluation of humoral and cell-mediated inducible immunity to Haemophilus ducreyi in an animal model of chancroid
Desjardins, M., Filion, L. G., Robertson, S., Kobylinski, L., & Cameron, D. W. (1996) · Infection and Immunity · doi:10.1128/iai.64.5.1778-1788.1996 · Cited by 16
Non-Specific Antibodies Induce Lysosomal Activation in Atlantic Salmon Macrophages Infected by Piscirickettsia salmonis
Pérez-Stuardo, D., Espinoza, A., Tapia, S., Morales-Reyes, J., Barrientos, C., Vallejos‐Vidal, E., Sandino, A. M., Spencer, E., Toro‐Ascuy, D., Rivas‐Pardo, J. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.544718 · Cited by 15
Overview of Biopharmaceuticals and Comparison with Small-molecule Drug Development
Reynolds, T., de Zafra, C., Kim, A., & Gelzleichter, T. R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394810-6.00001-0 · Cited by 16
Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan
Maitta, R. W. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.03.060 · Cited by 15
The History of Pneumococcal Disease
Gray, B. M., & Musher, D. M. (2014) · ASM Press eBooks · doi:10.1128/9781555815820.ch1 · Cited by 14
Current trends in targeted therapy for drug-resistant infections
Rahbarnia, L., Farajnia, S., Naghili, B., Ahmadzadeh, V., Veisi, K., Baghban, R., & Toraby, S. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10028-5 · Cited by 14
Novel strategies for controlling Streptococcus pyogenes infection and associated diseases: from potential peptide vaccines to antibody immunotherapy
Pandey, M., Sekuloski, S., & Batzloff, M. R. (2009) · Immunology and Cell Biology · doi:10.1038/icb.2009.29 · Cited by 14
Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant
Cirino, C. K., O'Loughlin, C., Gelder, F. B., Peterson, J. W., Sower, L. E., & Cirino, N. M. (2007) · Journal of Immune Based Therapies and Vaccines · doi:10.1186/1476-8518-5-11 · Cited by 14
Antibody-based therapy: An alternative for antimicrobial treatment in the post-antibiotic era
Luo, L., Li, Q., Chen, X., Li, C., Pan, Y., Sun, H., Yu, X., Wen, K., Shen, J., & Wang, Z. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127974 · Cited by 13
Parasites and immunotherapy: with or against?
Darani, H. Y., Yousefi, M., Safari, M., & Jafari, R. (2014) · Journal of Parasitic Diseases · doi:10.1007/s12639-014-0533-4 · Cited by 13
Antibody-based therapies as anti-infective agents
Casadevall, A. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.3.307 · Cited by 13
Self-citation
Bivalency Is Required for Anticapsular Monoclonal Antibodies To Optimally Suppress Activation of the Alternative Complement Pathway by theCryptococcus neoformansCapsule
Kozel, T. R., MacGill, R. S., & Wall, K. K. (1998) · Infection and Immunity · doi:10.1128/iai.66.4.1547-1553.1998 · Cited by 12
The Future of Antibody Therapy
Buelow, R., & van Schooten, W. (2007) · Ernst Schering Research Foundation workshop/Ernst Schering Foundation Symposium proceedings · doi:10.1007/2789_2007_040 · Cited by 12
Convalescent Plasma for Preventing Critical Illness in COVID-19: a Phase 2 Trial and Immune Profile
Sturek, J. M., Thomas, T. A., Gorham, J. D., Sheppard, C., Raymond, A. H., de Guex, K. P., Harrington, W., Barros, A. J., Madden, G. R., Alkabab, Y., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02560-21 · Cited by 11
Antibody Therapy: From Diphtheria to Cancer, COVID-19, and Beyond
Kumar, D., Gauthami, S., Bayry, J., Kaveri, S. V., & Hegde, N. R. (2021) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2021.0004 · Cited by 11
Mutational Analysis of Avidity and Fine Specificity of Anti-Levan Antibodies
Brorson, K., Thompson, C. D., Wei, G., Krasnokutsky, M. V., & Stein, K. E. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.12.6694 · Cited by 10
Use of convalescent plasma for COVID-19 in India
Khaire, N. S., Jindal, N., Yaddanapudi, L. N., Sachdev, S., Hans, R., Sachdeva, N. K., Singh, M. P., Agarwal, A., Mukherjee, A., Kumar, G., et al. (2021) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_3092_20 · Cited by 9
The potential of antibody-mediated immunity in the defence against biological weapons
Casadevall, A., & Pirofski, L. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.10.1359 · Cited by 9
Self-citation
Engineering Antibodies for the Treatment of Infectious Diseases
Fan, G., & Li, J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-72077-7_10 · Cited by 8
Capsular polysaccharide-protein conjugate vaccines and intravenous immunoglobulins
Sood, R. K., & Fattom, A. (1998) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.7.3.333 · Cited by 8
Convalescent Plasma in COVID-19
Banwait, R., Salabei, J. K., Fishman, T. J., & Iyer, U. G. (2020) · HCA Healthcare Journal of Medicine · doi:10.36518/2689-0216.1097 · Cited by 7
Immunoengineering: An Emerging Field in Infectious Diseases
Tatara, A. M., Mikos, A. G., & Kontoyiannis, D. P. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf209 · Cited by 7
Recovery of intact I g G in the gastrointestinal tract of the growing rat following ingestion of an ovine serum immunoglobulin
Balan, P., Han, K., Dukkipati, V. S. R., & Moughan, P. J. (2013) · Journal of Animal Physiology and Animal Nutrition · doi:10.1111/jpn.12060 · Cited by 7
Report on biopharmaceutical profile of recent biotherapeutics and insilco docking studies on target bindings of known aptamer biotherapeutics
Manibalan, S., Kandasamy, T., Varshni, M., Shobana, A., & Achary, A. (2020) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2020.1858395 · Cited by 7
COVID-19: Variants, Immunity, and Therapeutics for Non-Hospitalized Patients
Lee, C. Y. S., & Suzuki, J. B. (2023) · Biomedicines · doi:10.3390/biomedicines11072055 · Cited by 7
Efficiency and safety of convalescent plasma therapy in patients with COVID-19: a systematic review
Ostrovskaya, E. A., Костин, А. И., & Bulanov, А. Y. (2022) · Annals of critical care · doi:10.21320/1818-474x-2022-2-108-120 · Cited by 8
The Antigenome: From Protein Subunit Vaccines to Antibody Treatments of Bacterial Infections?
Giefing, C., Nagy, E., & von Gabain, A. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1132-2_9 · Cited by 7
Human Pharmaceuticals Produced in Plants
Larrick, J. W., Yu, L., Naftzger, C., Jaiswal, S., & Wycoff, K. L. (2002) · Springer eBooks · doi:10.1007/978-94-017-2693-1_4 · Cited by 7
Emergence of ancient convalescent plasma (CP) therapy: To manage COVID-19 pandemic
Dassarma, B., Tripathy, S., & Matsabisa, M. G. (2020) · Transfusion Clinique et Biologique · doi:10.1016/j.tracli.2020.11.004 · Cited by 6
The Forgotten Forefather: Joseph James Kinyoun and the Founding of the National Institutes of Health
Morens, D. M., & Fauci, A. S. (2012) · mBio · doi:10.1128/mbio.00139-12 · Cited by 6
Sialogenins and Immunomodulators Derived from Blood Feeding Parasites
Sá‐Nunes, A., & Oliveira, C. J. F. (2010) · Springer eBooks · doi:10.1007/978-90-481-9295-3_9 · Cited by 6
Immune Human Antibody Libraries for Infectious Diseases
Chan, S. K., & Lim, T. S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-72077-7_4 · Cited by 6
Antibody-based therapies for infectious diseases : renaissance for an abandoned arsenal?
Casadevall, A., Goldman, D. L., & Feldmesser, M. (1997) · Bulletin de l Institut Pasteur · doi:10.1016/s0020-2452(97)83532-5 · Cited by 6
Self-citation
An analysis of institutional arrangements for providing animal health services : a theoretical framework and empirical evidence from Kenya and Uganda
Ilukor, J. (2016) · University writing server of the University of Hohenheim (Universität Hohenheim) · Cited by 6
Plasma therapy: a passive resistance against the deadliest
Hansda, A., Biswas, D., Bhatta, A., Chakravorty, N., & Mukherjee, G. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.2006026 · Cited by 5
Experimental Animal Models of Invasive Fungal Infections
Imamura, Y. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-4 · Cited by 5
Egg Yolk Antibodies: Production and applications in the diagnosis and treatment of animal diseases - A review
Wani, M. Y., Pandit, A. A., Begum, J., Ahmed, N., Mir, M. S., & Makhdoomi, D. M. (2022) · Letters In Animal Biology · doi:10.62310/liab.v2i1.77 · Cited by 5
PNEUMOCOCCAL INFECTIONS
Dagan, R., Greenberg, D., Jacobs, M. R., & Phillips, B. L. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4044-6.50101-1 · Cited by 5
Acquired Antibody-Mediated Immunity to Fungi
Pirofski, L., & Casadevall, A. (2014) · ASM Press eBooks · doi:10.1128/9781555815776.ch33 · Cited by 4
Self-citation
The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case–control study
Nontawong, N., Siripongboonsitti, T., Tawinprai, K., Boonpratoom, M., Krailassiri, N., Boonkhum, C., Soonklang, K., Poovorawan, Y., & Mahanonda, N. (2022) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-022-00542-2 · Cited by 4
A Brief History of Polyclonal Antibody Therapies Against Bacterial and Viral Diseases Before COVID-19
Paneth, N., Walsh, M., Kornatowski, B. M., & Casadevall, A. (2024) · Current topics in microbiology and immunology · doi:10.1007/82_2024_279 · Cited by 4
Self-citation
History and Practice: Antibodies in Infectious Diseases
Hey, A. (2015) · ASM Press eBooks · doi:10.1128/9781555817411.ch1 · Cited by 4
COVID-19 Pandemic: A Remedial Measure Through Convalescent Serum
Abbas, S. N., Rauf, U., Saleem, A., Saleem, N., Basheer, T., Yaseen, S., Irfan, N., & Naushad, A. (2020) · International Journal of Innovations in Science and Technology · doi:10.33411/ijist/2020020202 · Cited by 4
Innate immune-mediated antiviral response to SARS-CoV-2 and convalescent sera a potential prophylactic and therapeutic agent to tackle COVID-19
Abdullah, A., Faisal, S., Aman, K., & Rahman, A. U. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa019 · Cited by 4
Preclinical Development of Monoclonal Antibodies
Meyer-Tamaki, K. B. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387815-1.00021-6 · Cited by 4
Streptococcal Infections
Gray, B. M. (1998) · Springer eBooks · doi:10.1007/978-1-4615-5327-4_35 · Cited by 4
Monoclonal antibodies
Pine, T. R. L., & Hill, H. R. (2001) · Seminars in Pediatric Infectious Diseases · doi:10.1053/spid.2001.19241 · Cited by 4
Convalescent plasma for COVID-19: planning for the next pandemic using the worldwide experience
Casadevall, A., Mattoon, E. R., Sullivan, D. J., Joyner, M. J., Franchini, M., & Focosi, D. (2025) · Clinical Microbiology Reviews · doi:10.1128/cmr.00060-24 · Cited by 4
Self-citation
A systematic review and meta-analysis of the seroconversion rates and adverse effects of COVID-19 mRNA vaccine and COVID-19 viral vector vaccine in kidney transplant recipient patients
Chen, S., Wei, W., Huang, F., Wang, J., Li, X., Geng, Z., Gao, F., Dong, T., Wei, P.-F., Yang, X., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2196893 · Cited by 3
Antibodies for the Prevention, Treatment, and Preemption of Infectious Diseases
Projan, S. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527699124.ch18 · Cited by 3
AAV-mediated delivery of a broadly neutralizing anti-flavivirus antibody protects against dengue and Zika viruses in a mouse model
Ko, H., Li, Y.-Y., Simanjuntak, Y., Yu, H.-P., Chiang, M., Lee, C.-Y., Liang, J., Lee, Y.-L., Sun, C., Wang, P.-S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.007 · Cited by 2
ANTICORPOS NA TERAPIA CONTRA O CÂNCER
Guimarães, M. C. C., Silva, I. V., & Rangel, L. B. A. (2008) · PerspectivasOnLine · Cited by 2
Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV and HPV
Wahid, B., Ali, A., Idrees, M., & Rafique, S. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2016.08.001 · Cited by 2
History of Antifungals
Lattif, A. A., & Swindell, K. (2009) · CRC Press eBooks · doi:10.3109/9780849387869-2 · Cited by 2
Emerging Preclinical and Clinical Applications of Theranostics for Nononcological Disorders
Assadi, M., Jokar, N., Yordanova, A., Gholamrezanezhad, A., Amini, A., Abbasi, F., Biersack, H., Amini, A. S., Nabipour, I., & Ahmadzadehfar, H. (2021) · PET Clinics · doi:10.1016/j.cpet.2021.03.009 · Cited by 2
Antibody-Based Therapies in Infectious Diseases
Oral, H. B., & Akdiş, C. A. (2000) · Methods in molecular medicine · doi:10.1385/1-59259-076-4:157 · Cited by 2
Regression of Atherosclerosis With Therapeutic Antibodies
Ginsburg, G. S. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.08.039 · Cited by 2
Specific Immunity and Cytokines
Casadevall, A., & Perfect, J. R. (2014) · ASM Press eBooks · doi:10.1128/9781555818241.ch8 · Cited by 2
Self-citation
Role of Antibody‐Mediated Immunity in Host Defense againstMycobacterium tuberculosis
Glatman‐Freedman, A., & Casadevall, A. (2004) · Wiley eBooks · doi:10.1128/9781555817657.ch32 · Cited by 2
Self-citation
Immunotherapy for Fungal Infections
Casadevall, A. (2002) · Humana Press eBooks · doi:10.1007/978-1-59259-171-8_18 · Cited by 1
Self-citation
Review on Antibody as A Drug of Choice
Yimer, L., Mideksa, K., & Ferede, B. (2017) · Archives on Veterinary Science and Technology · doi:10.29011/2637-9988/100012 · Cited by 1
Evaluation of the effectiveness of immunoglobulins in treatment of infectious diseases
Igityan, T., Burgasova, O., & Generalova, L. (2024) · Vrach · doi:10.29296/25877305-2024-03-01 · Cited by 1
Integrative and Emerging Models in Antibody Research: A Comprehensive Review
Devasani, J. R., Guntuku, G., sarabu, P., Muthyala, M. K. K., Palla, M. S., & Volety, M. S. (2025) · Antibody Therapeutics · doi:10.1093/abt/tbaf018 · Cited by 2
Antibacterial Drug Discovery in the 21st Century
Projan, S. J. (2007) · CRC Press eBooks · doi:10.1201/9781420008753.ch17 · Cited by 1
Preclinical Development of Monoclonal Antibodies
Meyer-Tamaki, K. B. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803620-4.00023-2 · Cited by 1
The Convalescent Plasma Craze! Where Does India Stand?
Priyadarsini, A. J., Karan, K., & Subramanian, A. (2021) · Journal of Laboratory Physicians · doi:10.1055/s-0041-1730753 · Cited by 1

Authors: Casadevall, A., & Scharff, M. D.
Affiliations: Albert Einstein College of Medicine (US)
ORCID: Casadevall, A
Scharff, M D
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 1994-08
Volume: 38
Issue: 8
Pages: 1695-1702
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.38.8.1695
PMC: PMC284624
OpenAlex: W2031152984
Cited by: 251
References: 84
Citations by year: 2025: 8 · 2024: 6 · 2023: 10 · 2022: 10 · 2021: 20 · 2020: 29 · 2019: 5 · 2018: 7 · 2017: 10 · 2016: 4 · 2015: 6 · 2014: 12 · 2013: 6 · 2012: 8
FWCI: 5.86
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA-39839)
National Institute of Allergy and Infectious Diseases (AI13342, AI33774, R01AI033774)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Keywords: serum therapy, animal models of infection, passive antibody therapy, passive immunization
MeSH terms: Animals, Disease Models, Animal, Humans, Immunization, Passive, Meningitis, Meningococcal, Pneumococcal Infections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Serum therapy revisited: animal models of infection and development of passive antibody therapy

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks